Satellos Announces Positive Functional Data from Phase 1b Open-Label Trial of SAT-3247 in Adults with Duchenne
Satellos Bioscience Inc. has announced encouraging data from the company’s Phase 1b open-label study of SAT-3247, an oral small molecule inhibitor of AAK, designed to address progressive muscle loss by restoring muscle regeneration in response…Learn More
